Literature DB >> 23054968

Safety of transradial approach for percutaneous coronary intervention in relation to body mass index: a report from a Japanese multicenter registry.

Yohei Numasawa1, Shun Kohsaka, Hiroaki Miyata, Akio Kawamura, Shigetaka Noma, Masahiro Suzuki, Susumu Nakagawa, Yukihiko Momiyama, Yuji Sato, Keiichi Fukuda.   

Abstract

Transradial coronary intervention (TRI) is commonly performed in Japan, but its efficacy may differ from that in Western countries, particularly given the smaller body habitus of Japanese patients. We compared the clinical outcomes of TRI with those of transfemoral coronary intervention (TFI) and evaluated their relationship with body mass index in a multicenter registry. We analyzed data from 1230 patients who underwent percutaneous coronary intervention (TRI 306, TFI 924) at 14 Japanese hospitals from September 2008 to August 2010. Multivariate logistic regression analysis was performed to evaluate the odds ratio regarding complications between TRI and TFI. Propensity scores were used to adjust for differences in TRI and TFI, extracting 274 matched patients from each group for comparisons. The overall complication rate was significantly lower (10.8 vs. 18.0%, p = 0.003) and the bleeding complication rate trended lower (4.6 vs. 7.6%, p = 0.088) in TRI than in TFI. TRI was moderately associated with a smaller bleeding risk after multivariable adjustment (OR 0.54; p = 0.072). After propensity score matching, TRI was associated with significantly lower complication rates compared with TFI (9.5 vs. 18.2%, p = 0.003), especially bleeding complications (3.3 vs. 9.9%, p = 0.002) and puncture site bleeding (1.1 vs. 5.5%, p = 0.004). Notably, bleeding rate was inversely related to body mass index in both groups. TRI appeared to be a safe alternative to TFI in this Japanese real-world multicenter registry, which includes high numbers of TRI.

Entities:  

Mesh:

Year:  2012        PMID: 23054968     DOI: 10.1007/s12928-012-0138-8

Source DB:  PubMed          Journal:  Cardiovasc Interv Ther        ISSN: 1868-4297


  5 in total

1.  Gender differences in in-hospital clinical outcomes after percutaneous coronary interventions: an insight from a Japanese multicenter registry.

Authors:  Yohei Numasawa; Shun Kohsaka; Hiroaki Miyata; Shigetaka Noma; Masahiro Suzuki; Shiro Ishikawa; Iwao Nakamura; Yutaro Nishi; Takahiro Ohki; Koji Negishi; Toshiyuki Takahashi; Keiichi Fukuda
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

2.  Impact of coronary dominance on in-hospital outcomes after percutaneous coronary intervention in patients with acute coronary syndrome.

Authors:  Toshiki Kuno; Yohei Numasawa; Hiroaki Miyata; Toshiyuki Takahashi; Koichiro Sueyoshi; Takahiro Ohki; Koji Negishi; Akio Kawamura; Shun Kohsaka; Keiichi Fukuda
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

3.  Impact of body mass index on in-hospital complications in patients undergoing percutaneous coronary intervention in a Japanese real-world multicenter registry.

Authors:  Yohei Numasawa; Shun Kohsaka; Hiroaki Miyata; Akio Kawamura; Shigetaka Noma; Masahiro Suzuki; Susumu Nakagawa; Yukihiko Momiyama; Kotaro Naito; Keiichi Fukuda
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

4.  Variation in in-hospital mortality and its association with percutaneous coronary intervention-related bleeding complications: A report from nationwide registry in Japan.

Authors:  Yuichi Sawayama; Kyohei Yamaji; Shun Kohsaka; Takashi Yamamoto; Yosuke Higo; Yohei Numasawa; Taku Inohara; Hideki Ishii; Tetsuya Amano; Yuji Ikari; Yoshihisa Nakagawa
Journal:  PLoS One       Date:  2021-12-13       Impact factor: 3.240

5.  Cost reduction associated with transradial access in percutaneous coronary intervention: A report from a Japanese nationwide registry.

Authors:  Satoshi Shoji; Shun Kohsaka; Hiraku Kumamaru; Kyohei Yamaji; Shiori Nishimura; Hideki Ishii; Tetsuya Amano; Kiyohide Fushimi; Hiroaki Miyata; Yuji Ikari
Journal:  Lancet Reg Health West Pac       Date:  2022-08-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.